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Abstract
Aims/hypothesis Gestational diabetesmellitus (GDM) is asso-
ciated with increased risks to mother and child, but globally
agreed diagnostic criteria remain elusive. Identification of
women with GDM is important, as treatment reduces adverse
outcomes such as perinatal death, shoulder dystocia and neo-
natal hypoglycaemia. Recently, the UK’s National Institute for
Health and Care Excellence (NICE) recommended new diag-
nostic thresholds for GDM which are different from the Inter-
national Association of the Diabetes and Pregnancy Study
Groups (IADPSG) criteria endorsed by the WHO. The study
aim was to assess neonatal and obstetric outcomes among
women who would test positive for the IADPSG criteria but
negative for the NICE 2015 criteria.
Methods Data from 25,543 consecutive singleton live births
(2004–2008) were obtained retrospectively from hospital re-
cords. Women were screened with a random plasma glucose
(RPG; 12–16 weeks) and a 50 g glucose challenge test (GCT;
26–28 weeks). If RPG >7.0 mmol/l, GCT >7.7 mmol/l or
symptoms were present, a 75 g OGTTwas offered (n=3,848).
Results In this study, GDM prevalence was 4.13% (NICE
2015) and 4.62% (IADPSG). Women who ‘fell through the
net’, testing NICE-negative but IADPSG-positive (n=387),
had a higher risk of having a large-for-gestational-age
(LGA) infant (birthweight >90th percentile for gestational
age; adjusted OR [95% CI] 3.12 [2.44, 3.98]), Caesarean de-
livery (1.44 [1.15, 1.81]) and polyhydramnios (6.90 [3.94,
12.08]) compared with womenwith negative screening results
and no OGTT (n=21,695). LGA risk was highest among
women with fasting plasma glucose 5.1–5.5 mmol/l (n=
167): the mean birthweight was 350 g above that of the refer-
ence population and 37.7% of infants were LGA.
Conclusions/interpretation The IADPSG criteria identify
women at substantial risk of complications who would not
be identified by the NICE 2015 criteria.
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Introduction
Gestational diabetes mellitus (GDM), defined as carbohydrate
intolerance causing hyperglycaemia with first onset or recog-
nition in pregnancy [1, 2], is increasing in incidence in many
populations worldwide as obesity becomes more prevalent
[3]. Untreated GDM results in poor maternal and fetal out-
comes: women with GDM are more likely to suffer pre-
eclampsia, operative delivery and stillbirth [4], and infants
are at higher risk of preterm delivery and macrosomia or large
for gestational age (LGA), which is associated with birth in-
jury, respiratory distress and neonatal hypoglycaemia [5]. In
the longer term, children born to mothers with GDM are at
greater risk of obesity and type 2 diabetes in later life, a phe-
nomenon attributed to the effects of intrauterine exposure to
hyperglycaemia [6, 7].
Fortunately, many of these risks can be reduced by identi-
fication of GDM pregnancies and prompt intervention to re-
duce maternal antenatal hyperglycaemia [8, 9]. One barrier to
case identification has been the lack of a universally accepted
set of diagnostic criteria for GDM. The International Associ-
ation of the Diabetes and Pregnancy Study Groups (IADPSG)
proposed diagnostic criteria which were based upon an OR of
1.75 for negative pregnancy outcomes (Table 1) using data
from the Hyperglycaemia and Adverse Pregnancy Outcomes
(HAPO) study (75 g OGTT 0 h ≥5.1 mmol/l, 1 h ≥10.0 mmol/
l, 2 h ≥8.5 mmol/l) [10, 11]. However, these criteria used
lower fasting plasma glucose (FPG) thresholds than other
criteria in common use (Table 1) and added a 1 h criterion,
leading to concerns about increased diagnosis rates, resource
allocation and increased medicalisation of pregnancy [12, 13].
The IADPSG criteria have been adopted by the WHO [2] and
the ADA [14] but were not endorsed at the National Institutes
of Health summit in the USA [12] nor by the National Institute
for Health and Care Excellence (NICE) in the UK due to
concerns about treatment costs and the limited evidence of
benefit for treating at lower diagnostic thresholds. NICE pro-
posed alternative criteria for adoption in 2015 (75 g OGTT 0 h
≥5.6 mmol/l; 2 h ≥7.8 mmol/l) [15].
The aim of the current study was to retrospectively com-
pare outcomes among women who would test positive for the
IADPSG criteria for GDM but negative for NICE 2015 diag-
nostic criteria.
Methods
Population and standard care Data from all singleton preg-
nancies (2004–2008) at Cambridge University Hospitals
National Health Service Foundation Trust were obtained ret-
rospectively from hospital medical and obstetric records as
part of an approved service evaluation. At that time in our
institution all pregnant women were invited to be screened at
antenatal booking with a random plasma glucose (RPG; n=
17,736; typically at 12–16 weeks’ gestation). Women with
RPG >7.0 mmol/l or a previous diagnosis of GDM were of-
fered a 75 g OGTT. All women without known GDM/pre-
existing diabetes were screened at 26–28 weeks with a 50 g
glucose challenge test (GCT). Women with a GCT result
>7.7 mmol/l were then referred for a 75 g OGTT [16]. Addi-
tional OGTTs were performed in later pregnancy if symptoms
were present. Therefore, all women who had an OGTT (n=3,
848) had already had at least one abnormal result on glucose
testing during pregnancy, symptoms consistent with
hyperglycaemia, or GDM in a previous pregnancy. Women
with known pre-existing diabetes were excluded from the
study. The WHO 1999 criteria were used for GDM diagnosis
until August 2007 (75 g OGTT 0 h ≥7.1 mmol/l; 2 h
≥7.8 mmol/l) and the modified WHO 1999 criteria thereafter
(75 g OGTT 0 h ≥6.1 mmol/l; 2 h ≥7.8 mmol/l; Table 1).
Following diagnosis, women with GDM were seen every 2–
4 weeks at a multidisciplinary clinic, encouraged to monitor
their blood glucose levels and offered lifestyle counselling.
Women who had evidence of persistent hyperglycaemia were
offered treatment with insulin, metformin or both [17]. Wom-
en with GDM were offered regular ultrasound scans during
pregnancy (at 12, 20, 28 and 36 weeks), whereas non-diabetic
women usually have two routine ultrasound scans (at 12 and
20 weeks).
Laboratory analysis Both venous and capillary samples
were used during 2004 and 2008 for glucose testing in our
institution. Venous blood was collected using fluoride oxalate
tubes and analysed using a hexokinase method (Dimension
RxL Max Clinical Chemistry System; Siemens Healthcare
Diagnostics, Deerfield, IL, USA) in our laboratory accredited
by Clinical Pathology Accreditation, UK. Capillary samples
were analysed using the Bayer Elite glucose monitoring sys-
tem (Bayer, Newbury, UK). Although both laboratory and
point-of-care methods were regularly calibrated, small differ-
ences exist between capillary and venous glucose testing [18].
The same diagnostic criteria were used for both capillary and
venous tests.
Definitions Macrosomia was defined as birthweight >4 kg.
LGA was defined as birthweight >90th percentile for gesta-
tional age and was calculated for babies born at 24–41 weeks’
gestation using the WHO weight percentile calculator with a
mean birthweight of 3,542 g (SD 437 g) (World Health Orga-
nisation Weight percentiles calculator, available from www.
who.int/reproductivehealth/topics/best_practices/weight_
percentiles_calculator.xls; accessed 20 April 2015) [19–21].
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Pre-eclampsia was defined as systolic blood pressure
≥140 mmHg and/or diastolic blood pressure ≥90 mmHg on
two or more occasions with proteinuria ≥1+ on dipstick. Pa-
tients with no blood pressure recorded who were on the pre-
eclampsia treatment pathway before or during labour were
also considered to have pre-eclampsia. Patients with chronic
hypertension prior to pregnancy were not considered to have
pre-eclampsia. Preterm delivery was defined as delivery prior
to 37 weeks’ gestation. Polyhydramnios was defined as ex-
cessive amniotic fluid, corresponding to the deepest vertical
pool ≥8 cm on ultrasound or an amniotic fluid index >95th
percentile for the corresponding gestational age. Antepartum
haemorrhage was defined as any blood loss from the vagina
after the 24th week of gestation. Postpartum haemorrhage was
defined as blood loss of >500 ml following delivery, or the
requirement for a blood transfusion.
Statistical analysis Data were collected for demographic in-
formation, glucose screening results and pregnancy outcomes.
Women were classified into groups according to their OGTT
results: OGTT not done; NICE-negative IADPSG-negative;
NICE-positive IADPSG-positive; NICE-negative IADPSG-
positive; and NICE-positive IADPSG-negative (Table 1,
Fig. 1). Groups were further divided according to the OGTT
criterion that was abnormal. Women could test positive for
some but not all GDM diagnostic criteria by having an FPG
5.1–5.5 mmol/l (IADPSG-only 0 h group), an OGTT 1 h glu-
cose ≥10.0 mmol/l (IADPSG-only 1 h group) or an OGTT 2 h
glucose 7.8–8.4 mmol/l (NICE-only 2 h group, which was
also the NICE-positive IADPSG-negative group) (Table 1,
Fig. 1).
Participant characteristics are presented as n (%) for cate-
gorical data and mean (95% CI) for continuous data. Differ-
ences between each OGTT classification group and the refer-
ence population were tested using Fisher’s exact test and lin-
ear regression, respectively. The reference population was
considered to be all women who did not have an OGTT (n=
21,695). These women had a GCT result <7.8 mmol/l, but
some might have had fasting hyperglycaemia that would not
have been identified using the GCT.
Associations between GDM classification group and ma-
ternal or fetal outcomes compared with the reference
population were estimated using logistic regression, and re-
sults are presented as ORs (95%CIs). Results are presented as
unadjusted models and models which were adjusted for po-
tential confounders [10]. Analyses of LGA, small for gesta-
tional age (SGA; birthweight <10th percentile for gestational
age) and pre-eclampsia outcomes were adjusted for maternal
BMI, maternal age, parity, maternal smoking and ethnicity.
These analyses were not adjusted for gestational age at birth,
as it was not considered a true confounder for pre-eclampsia,
and LGA and SGA already incorporate gestational age within
their definitions. Macrosomia, Caesarean section (CS), instru-
mental delivery, stillbirth, infant admission to the neonatal
intensive care unit (NICU), polyhydramnios, ante- or postpar-
tum haemorrhage, and 1 or 5 min Apgar scores were adjusted
for maternal BMI, maternal age, parity, maternal smoking,
ethnicity and estimated gestational age at birth. The preterm
delivery outcome was adjusted for maternal BMI, maternal
age, parity, maternal smoking, ethnicity, pre-eclampsia and
antepartum haemorrhage. To make allowance for multiple
testing, a significance level of p≤0.001 was considered sig-
nificant and p≤0.01 was considered a trend. Statistical analy-
sis was performed using Stata version 12.0 software
(StataCorp LP, College Station, TX, USA).
Results
Records were obtained for 25,789 births; 25,543 records were
included in the analysis after exclusion of pregnancies
resulting in miscarriage (n=59) or termination (n=65), those
with no birthweight information (n=3), duplicate data (n=20)
and records consistent with overt diabetes (RPG ≥11.1 mmol/l
at booking; n=99). Over 99.9% of records had data available
for pregnancy outcome, mode of delivery and antenatal com-
plications; 84.9% of records had data available for their usual
maternal adult BMI. Characteristics of the study population
are described in Table 2.
A total of 3,848 (15.1%) antenatal OGTTs were performed,
of which 2,406 (62.5%) were negative for GDM according to
both IADPSG and the proposed NICE 2015 criteria, and 794
women (20.6%) had GDM according to both IADPSG and
NICE 2015 criteria. In this study, the prevalence of GDMwas
Table 1 Current and recent criteria used for diagnosis of GDM based on the OGTT
OGTT criterion IADPSG, WHO 2013
and ADA 2014 [11]
WHO 1999 Modified WHO 1999 Proposed NICE 2015 ACOG
Diagnostic requirements One abnormality
on 75 g OGTT
One abnormality
on 75 g OGTT
One abnormality
on 75 g OGTT
One abnormality
on 75 g OGTT
Two abnormalities
on 100 g OGTT
FPG, mmol/l (mg/dl) ≥5.1 (≥92) ≥7.1 (≥128) ≥6.1 (≥110) ≥5.6 (≥101) ≥5.3 (≥95)
OGTT 1 h glucose, mmol/l (mg/dl) ≥10.0 (≥180) – – – ≥10.0 (≥180)
OGTT 2 h glucose, mmol/l (mg/dl) ≥8.5 (≥153) ≥7.8 (≥140) ≥7.8 (≥140) ≥7.8 (≥140) ≥8.6 (≥154)
OGTT 3 h glucose, mmol/l (mg/dl) – – – – ≥7.8 (≥140)
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4.13% (1,055/25,543), using NICE 2015 criteria, and 4.62%
(1,181/25,543) according to the IADPSG criteria. Using the
IADPSG criteria instead of the proposed NICE 2015 criteria
would have resulted in treating 126 more women over 5 years.
Although these 126 women represented only 0.49% of preg-
nancies, they accounted for 3.82% of cases of LGA, 2.68% of
cases of pre-eclampsia and 5.30% of cases of polyhydramnios.
Overall, 3,010 (12.2%) infants had a birthweight above the
90th percentile, of whom 207 (6.9%) mothers had been offered
treatment for hyperglycaemia.
Characteristics of women with abnormal glucose tests As
expected, women with GDM diagnosed by any method were
older and had a higher BMI compared with the general pop-
ulation (Table 2). Pregnancies complicated by one or more
abnormal glucose values yielded an infant with a higher
birthweight (Tables 2, 3). Women who were offered treatment
for GDM delivered infants with an average birthweight of 3,
437 g and a higher rate of macrosomia (adjusted OR 1.49
[1.21, 1.84]) and LGA (adjusted OR 1.84 [1.54, 2.20]) com-
pared with the reference population, after adjustment for
maternal age, parity, BMI, smoking status and ethnicity (and
estimated gestational age at birth for macrosomia outcome).
Women who had GDM by any criteria or both criteria were
more likely to have a CS delivery and to suffer from pre-
eclampsia compared with the reference population.
Pregnancies where an OGTT was performed that was
negative for GDM according to the NICE and IADPSG
criteria (NICE-negative IADPSG-negative) were at
higher risk of macrosomia (16.8%; unadjusted OR 1.60
[1.42, 1.79], adjusted OR 1.52 [1.34, 1.73]), LGA
(16.9%; unadjusted OR 1.75 [1.56, 1.96], adjusted OR
1.63 [1.44, 1.84]), CS delivery (33.9%; unadjusted OR
1.55 [1.42, 1.70], adjusted OR 1.36 [1.23, 1.51]) (espe-
cially emergency CS [19.7%; unadjusted OR 1.45 (1.30,
1.61), adjusted OR 1.31 (1.16, 1.47)]), pre-eclampsia
(7.2%; unadjusted OR 1.40 [1.18, 1.65], adjusted model
did not show a significant effect) and polyhydramnios
(4.4%; unadjusted OR 8.15 [6.26, 10.61], adjusted OR
7.90 [5.94, 10.53]) compared with the reference popula-
tion. These women had abnormal glucose tests on
screening and/or a history of previous GDM.
IADPSG-positive
NICE 2015-negative
BW: 3,612.1
(3,551.1, 3,673.1) g
n=387; 29.7% LGA
Treatment offered to 0%
NICE 2015-positive
IADPSG-negative
BW: 3,360.7
(3,294.7, 3,426.8) g
n=261; 11.5% LGA
Treatment offered to 
100%
NICE 2015-positive
IADPSG-positive
BW: 3,487.1 
(3,446.2, 3,528.0) g
n=794; 24.6% LGA 
Treatment offered 
to 95.2%
IADPSG-positive
n=1,181
NICE 2015-positive
n=1,055
Pregnant population with 
at least one abnormal 
glucose screening test but 
confirmed negative for 
GDM by both
NICE 2015 and IADPSG 
criteria
BW: 3,496.6 
(3,473.9, 3519.3) g
n=2,406; 16.9% LGA
Treatment offered to 0%
All OGTTs performed
n=3,848
Falling through the net:
Positive on some but not all OGTT criteria for GDM
IADPSG-only 0 h
OGTT 0 h value 5.1−
5.5 mmol/l; BW: 3,711.1 
(3,619.0, 3,803.2) g
n=167; 37.7% LGA
Treatment offered to 0%
IADPSG-only 1 h
OGTT 1 h value >10 mmol/l; 
BW: 3,574.2 (3,503.4,
3,645.0) g
n=288; 26.0% LGA
Treatment offered to 0%
NICE-only 2 h
OGTT 2 h value 7.8−8.4 mmol/l; 
BW: 3,360.7 
(3,294.7, 3,426.8) g
n=261; 11.5% LGA
Treatment offered to 100%
Reference population: OGTT not done
Healthy pregnant women with no positive glucose screening tests 
Presumed: NICE 2015-negative, IADPSG-negativea
BW: 3,360.7 g (3,352.6, 3,368.8)
n=21,695; 10.4% LGA
Treatment offered to 0%
Fig. 1 Classification of pregnant
women according to GDM
diagnosis. Data are mean (95%
CI). BW, birthweight; LGA
classified as BW >90th percentile
for gestational age. aThis group
may contain some patients with
undiagnosed GDM due to fasting
hyperglycaemia that is not
identified by the GCT
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Women who were NICE-positive IADPSG-negative on
OGTTwere offered treatment and had an LGA rate compara-
ble to that of the reference population (adjusted OR 1.10 [0.73,
1.65]; 11.5% vs 10.4%; Table 3). Overall, there was a trend for
increased CS rates in this group (adjusted OR 1.53 [1.16, 2.02;
p=0.003]), but there was no increase in emergency CS rates
(adjusted OR 1.12 [0.80, 1.58]). Pregnancies in this category
were at increased risk of polyhydramnios (adjusted OR 6.13
[2.93, 12.76]) but not of pre-eclampsia (adjusted OR 1.58
[1.01, 2.47]) compared with the reference population.
Interestingly, women in the NICE-negative IADPSG-posi-
tive category who were untreated had the highest rate of LGA
in this study (29.7%; adjusted OR 3.12 [2.44, 3.98]). These
women were at higher risk of emergency CS delivery (adjust-
ed OR 1.60 [1.24, 2.06]) and polyhydramnios (adjusted OR
6.90 [3.94, 12.08]) compared with the reference population.
Women who fall through the net with NICE 2015: identi-
fying the group at highest risk of LGA and other adverse
outcomes Women in both the IADPSG-only 0 h and IADP
SG-only 1 h groups were at high risk of LGA, CS delivery and
emergency CS compared with the reference population, but
the risks were higher for the IADPSG-only 0 h group: 37.7%
and 26.0% of IADPSG-only 0 h and IADPSG-only 1 h preg-
nancies, respectively, yielded an LGA infant. Infants in the
IADPSG-only 0 h group had a mean birthweight of
3,711.1 g: 350.4 g higher than infants from the reference pop-
ulation. They also had a trend for an increased risk of having a
low 1 min Apgar score (adjusted OR 2.16 [1.30, 3.60]; p=
0.003). Pregnancies in the IADPSG-only 1 h group had the
greatest risk of polyhydramnios (adjusted OR 7.46 [4.06,
13.72]) and pre-eclampsia (unadjusted OR 2.24 [1.54, 3.25])
when compared with the reference population. However,
when adjustment was made for maternal BMI, age, parity,
smoking, ethnicity and estimated gestational age at birth, the
risk of pre-eclampsia was no longer significant.
Overall, 20.4% of women who were offered treatment for
hyperglycaemia in pregnancy had an LGA infant. Although
many of these women had more severe hyperglycaemia, this
information was used to give a conservative estimate for the
number needed to treat (NNT) to prevent one case of LGA in
the groups which did not receive treatment. NNTs for the
IADPSG-only 0 h and IADPSG-only 1 h groups were 5.8
and 17.9, respectively.
Discussion
In this study, the prevalence of GDM in the study population
was 4.13% using NICE 2015 criteria and 4.62% using IADP
SG criteria. Using the IADPSG criteria instead of the pro-
posed NICE 2015 criteria would have resulted in treating
126 more women over 5 years. Using the proposed NICE
2015 criteria would have resulted in 0.49% fewer women
being offered treatment but would have failed to identify
3.82% cases of LGA, 2.68% cases of pre-eclampsia and
5.30% cases of polyhydramnios.
In this study, the women at highest risk of having an LGA
infant were those who had an abnormal OGTT but ‘fell
through the net’ between the IADPSG and NICE 2015 diag-
nostic cut-offs for GDM. Many of these women were not
identified according to the diagnostic thresholds used at the
time in our institution (75 g OGTT 0 h ≥6.1 mmol/l or
≥7.1 mmol/l; 2 h ≥7.8 mmol/l) and therefore were not offered
t rea tment . Women with more severe degrees of
hyperglycaemia were offered treatment and their offspring
had a much lower risk of being LGA. Previous reports have
suggested that offering treatment to women with modest de-
grees of hyperglycaemia in pregnancy results in a reduction in
birthweight of 100–140 g [13]. However, in this study, women
with an FPG 5.1–5.5 mmol/l (IADPSG-only 0 h) gave birth to
infants with a very high rate of LGA (37.7%) and a mean
birthweight 350 g higher than that of the reference population
and 274 g higher than that of women with treated
hyperglycaemia. A detailed cost–benefit analysis was beyond
the scope of this project, but an NNT of 5.8 for this group
suggests that treatment may be economical depending upon
the expected risks in the population and compares favourably
to other interventions in diabetes [22].
This study has several strengths. Data were collected on all
singleton pregnancies at our institution between 2004 and
2008. This allows the assessment of outcomes and risk in a
real-life clinical setting. Unlike many prospective clinical
studies, the individuals were not highly selected and there
was no difference between their care and standard clinical care
at the time. However, this was a single centre study in a pop-
ulation with relatively low levels of ethnic diversity. Overall,
the prevalence of GDM in our population was relatively low.
Higher incidence rates for hyperglycaemia in pregnancy have
been reported in other regions worldwide [23]. The IADPSG
guidelines [11] now recommend screening pregnant women
who are not known to have diabetes at 24–28weeks’ gestation
using the OGTT and not the GCT. The use of the OGTT for
universal screening of pregnant women may be associated
with an increase in the prevalence of GDM in our population.
However, the increased use of the OGTTalso makes the issue
of ‘falling through the net’ more important, as the number of
women who test positive for the IADPSG and negative for the
NICE 2015 criteria will be higher.
Using a retrospective study design confers some disadvan-
tages. First, the screening protocol in use at the time used a
GCT to exclude women who did not need an OGTT. Women
with fasting hyperglycaemia, shown in this study to be at risk
of adverse outcomes, would not have been readily identified
using a GCT, which relies on a 1 h post-load test only. How-
ever, if these women had been removed from the analysis, the
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reference population would have been lower risk overall and
the differences in outcome between reference and study pop-
ulations would have been similar or more marked. Although
screening tests were offered to all pregnant women, a minority
might have chosen not to be screened, or not to attend for an
OGTT if an initial screening test was positive. All women
meeting predetermined criteria were offered dietary advice
and other treatment, but response to treatment offered, the
nature and dose of such treatments, and adherence to any
advice or treatments received are unclear. Women with
GDM received more antenatal scans and appointments and
may be at greater risk of interventions or conditions such as
pre-eclampsia and polyhydramnios through increased contact
with health professionals. Although we cannot adequately
control for this, it is interesting to note that women who were
NICE-negative IADPSG-positive also had increased rates of
pre-eclampsia and CS despite being considered not to have
GDM at the time. Some capillary blood glucose samples were
used in place of venous plasma for blood glucose measure-
ment, which might have introduced small variations in mea-
sured glucose concentrations. A further consideration is that
following an abnormal GCT result, some women might have
instituted lifestyle change prior to OGTT testing, producing a
better-than-expected OGTT result. While lifestyle change has
been shown to improve glucose tolerance in obese pregnant
women [24], the 1–2 week window between an abnormal
GCT and a follow-up OGTT gives limited time for this, and
further opportunities for GDM diagnosis were available later
in pregnancy for women with symptoms or ultrasound fea-
tures consistent with macrosomia. Information on neonatal
sex was unavailable and therefore sex-specific criteria for
LGA could not be used [25]. Although the sample size was
large overall, the number of women in certain subgroups was
too small to enable meaningful analysis of rare outcomes such
as stillbirth. A 75 g OGTT was used, rather than the 100 g
OGTT favoured by the American College of Obstetricians and
Gynecologists (ACOG), which does not permit direct com-
parisons to be made with the ACOG diagnostic criteria. How-
ever, the ACOG criteria (100 g OGTT 0 h ≥5.3 mmol/l; 1 h
≥10.0 mmol/l; 2 h ≥8.6 mmol/l; 3 h ≥7.8 mmol/l) will also
identify many women with fasting hyperglycaemia, although
as two abnormal results are required to make a diagnosis not
all in this group would be offered treatment.
There is a fundamental difference between the IADPSG
and NICE 2015 criteria. The IADPSG criteria are grounded
on minimising the risk of harm to the mother and baby, and
diagnostic thresholds were set to give an OR of 1.75 at each
OGTT time point [11]. One of the challenges in ascertaining
GDM-related risks in pregnancy is the large number of rela-
tively infrequent adverse outcomes that have not shown con-
sistent evidence of a significant association with GDM. For
example, in the current study of 25,543 pregnancies, there
were insufficient events to determine any effect of GDM
classification on stillbirth rates or maternal admission to inten-
sive care, and there was no evidence of altered rates of infant
admission to the NICU. However, despite these concerns, the
IADPSG criteria have been shown to be cost-effective, at least
partly because of a reduction in the risk of infrequent adverse
effects such as NICU admission [26]. Conversely, the NICE
2015 criteria have been based upon reducing historical aver-
age National Health Service unit costs for selected adverse
outcomes (those common enough to have statistical power
to be detected in randomised controlled studies) using health
economic modelling. While cost-effectiveness is important in
any healthcare system, the burden of psychological and emo-
tional distress caused bymany complications is also important
and cannot be measured in economic terms alone. GDM di-
agnostic criteria should aim to identify women at risk of com-
plications in the first instance, although not all these women
may require pharmacological treatment. Future work should
focus on accurate identification of women with GDMwho are
at low risk of complications and who might be suitable for
community-based lifestyle interventions.
This study demonstrates a significant risk of LGA among
infants of women who meet the IADPSG criteria for GDM
who would be unidentified and untreated using many criteria
in current clinical use (WHO 1999, modified WHO 1999 and
proposed NICE 2015) [27]. One barrier to adoption of the
IADPSG criteria for GDM has been the widespread concern
about increased case identification rates and increased treat-
ment rates leading to increased costs with purportedly little
outcome data to support such a change [12]. Some reports
have suggested that diagnosis rates of GDM would increase
dramatically under the IADPSG criteria [13]. The current
dataset suggests that adopting the IADPSG criteria over the
NICE 2015 guidelines would be associated with a small in-
crease in the prevalence of GDM from 4.13% to 4.62% in this
population if screening protocols were unchanged (an addi-
tional 25.2 patients per year). Worryingly, these data suggest
that if the NICE 2015 criteria were adopted instead of the
IADPSG criteria a group of high-risk women would be un-
identified and undertreated (IADPSG-only 0 h) and a group of
low-risk women (NICE-only 2 h) would be treated instead.
This suggests that despite being based upon cost-effective-
ness, the NICE criteria may not necessarily facilitate the allo-
cation of resources to address those most at risk of adverse
outcomes.
The IADPSG criteria include women with an FPG 5.1–
5.5 mmol/l and an OGTT 1 h glucose ≥10.0 mmol/l who,
untreated, were associated with a high risk of delivering
LGA infants in this study. The IADPSG criteria exclude wom-
en who have an OGTT 2 h glucose 7.8–8.4 mmol/l, who were
found in this study to have a very low risk of LGA in their
offspring (11.5%). Although many in this group would have
been offered treatment, a confounding factor, the low rate of
LGA, suggests that some of these women could be safely
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untreated. Interestingly, these treated women had a lower in-
cidence of LGA among their infants compared with untreated
women who had an OGTT that was negative for GDM ac-
cording to both NICE and IADPSG criteria despite having
abnormal screening tests or previous GDM. The offspring of
these womenwith a negative OGTT had a 16.9% risk of LGA,
significantly higher than that of the reference population. The-
se resu l t s conf i rm tha t women wi th border l ine
hyperglycaemia who have positive screening tests but who
do not meet the diagnostic thresholds for GDM are also at
increased risk of adverse outcomes. This finding suggests that
standard dietary and lifestyle advice given in GDM might
benefit even non-GDM women in pregnancy and could be
given more widely.
One issue which has prevented widespread adoption of the
IADPSG diagnostic criteria is the concern about unnecessarily
over-medicalising healthy pregnancies [13]. In this study,
even women with a negative OGTT were at higher risk of
CS delivery compared with the reference population. The
highest risks of CS delivery in this study were seen in women
with a positive OGTT (NICE-positive IADPSG-positive) and
in women with an FPG 5.1–5.5 mmol/l (IADPSG-only 0 h).
Recommendations to offer induction at 38 weeks to women
with treated GDM are likely to explain the increased rates of
emergency CS in the NICE-positive IADPSG-positive group
due to the risk of failed induction [17]. However, the IADP
SG-only 0 h group had higher rates of emergency CS delivery
overall, suggesting that women with unidentified
hyperglycaemia had increased intervention rates despite being
considered GDM-negative according to the diagnostic criteria
in use in our institution at the time. These findings suggest that
intervention rates may be related to glucose per se rather than
diagnostic categorisation using the OGTT.
In summary, women who fall through the net, who would
test positive for GDM according to the IADPSG criteria but
not the NICE 2015 criteria, had the highest risk of having
infants with LGA in this retrospective study compared with
women in the reference population or those with more severe
degrees of hyperglycaemia who were offered treatment.
Women with FPG levels 5.1–5.5 mmol/l were at particularly
high risk of CS delivery and LGA. Conversely, women with
an OGTT 2 h glucose 7.8–8.4 mmol/l, who would have had
GDM according to the NICE 2015 criteria but not the IADP
SG criteria, were offered treatment and had an extremely low
incidence of LGA. These data demonstrate that the IADPSG
criteria identify women at substantial risk of LGA who may
benefit from treatment while excluding women whomay have
a low risk of adverse pregnancy outcomes.
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